华润置地拟以2.01亿元收购华润生命科学100%股权
华润置地（01109）发布公告，2025年5月23日，公司间接全资附属公司与卖方及目标公司（指：华润生命科学产业发展有限公司）签署股权转让协议，买方同意以2.01亿元（约2.18亿港元）收购目标公司100%的股权。
此次收购构成公司的关联交易，由于适用百分比率低于5%，因此仅需遵守申报及公告规定，免于独立股东批准。目标公司截至2024年12月31日的财务数据显示，除税前亏损约为3355万元，除税后亏损约为6793万元，账面净值约为1.82亿元。
此次收购的代价参考了目标股权的评估价值、卖方的股东贷款及整体市况，并由独立估值师确认。收购事项的完成需满足若干先决条件，包括相关内部批准程序的完成及尽职调查的通过。完成后，目标公司将成为公司的间接全资附属公司。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10